Increased circulating levels of osteoclastogenesis inhibitory factor (osteoprotegerin) in patients with chronic renal failure
- 1 March 2002
- journal article
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 39 (3) , 525-532
- https://doi.org/10.1053/ajkd.2002.31402
Abstract
No abstract availableKeywords
This publication has 42 references indexed in Scilit:
- In Vivo Demonstration that Human Parathyroid Hormone 1–38 Inhibits the Expression of Osteoprotegerin in Bone with the Kinetics of an Immediate Early GeneJournal of Bone and Mineral Research, 2000
- Immunological Characterization of Circulating Osteoprotegerin/Osteoclastogenesis Inhibitory Factor: Increased Serum Concentrations in Postmenopausal Women with OsteoporosisJournal of Bone and Mineral Research, 1999
- Osteoclastogenesis Inhibitory Factor (OCIF) Directly Inhibits Bone-Resorbing Activity of Isolated Mature OsteoclastsBiochemical and Biophysical Research Communications, 1998
- Osteoprotegerin Production by Human Osteoblast Lineage Cells Is Stimulated by Vitamin D, Bone Morphogenetic Protein-2, and CytokinesBiochemical and Biophysical Research Communications, 1998
- Osteoclast Differentiation Factor (ODF) Induces Osteoclast-like Cell Formation in Human Peripheral Blood Mononuclear Cell CulturesBiochemical and Biophysical Research Communications, 1998
- Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and ActivationCell, 1998
- Predictive value of serum parathyroid hormone levels for bone turnover in patients on chronic maintenance dialysisAmerican Journal of Kidney Diseases, 1995
- Bone disease in predialysis, hemodialysis, and CAPD patients: Evidence of a better bone response to PTHKidney International, 1995
- Role of 1,25-dihydroxyvitamin D on the skeletal resistance to parathyroid hormoneKidney International, 1987
- Skeletal resistance to the calcemic action of parathyroid hormone in uremia: Role of 1,25(OH)2D3Kidney International, 1976